Imlifidase:优化接受艾美赛珠单抗治疗的A型血友病患者管理的新选择
艾美赛珠单抗可预防但不能治疗急性出血,对存在FVIII抑制物的患者急诊管理尤为复杂。本研究在抑制物阳性A型血友病小鼠中探究IdeS(Imlifidase)联合艾美赛珠单抗的作用,发现IdeS可水解艾美赛珠单抗并清除抗FVIII IgG,恢复外源性FVIII止血疗效,且不受艾美赛珠单抗及多克隆人IgG影响。
要点
- IdeS在体外和体内均可水解艾美赛珠单抗,但速率慢于另一种重组人单克隆IgG4。
- IdeS介导的抑制物清除及外源性FVIII止血恢复不受艾美赛珠单抗和多克隆人IgG影响。
- 作者认为IdeS可用于接受艾美赛珠单抗预防的抑制物阳性A型血友病患者,以改善突破性出血或择期大手术的管理。
核心结论
- 作者认为,IdeS可给予接受艾美赛珠单抗预防的抑制物阳性A型血友病患者,以改善和简化突破性出血或择期大手术的管理。
研究设计与样本
- 在重建人中和性抗FVIII IgG并接受艾美赛珠单抗治疗的A型血友病小鼠中注射IdeS。
主要发现
- IdeS在体外和体内水解艾美赛珠单抗,但速率慢于另一种重组人单克隆IgG4。
- F(ab')2片段迅速从循环中清除,导致艾美赛珠单抗促凝血活性快速丧失,而少量单切割中间体IgG持续数天。
- 在抑制物阳性A型血友病小鼠中,艾美赛珠单抗和多克隆人IgG的存在未损害IdeS介导的中和性抗FVIII IgG清除及外源性FVIII止血疗效的恢复。
临床怎么用
- 作者认为,IdeS可给予接受艾美赛珠单抗预防的抑制物阳性A型血友病患者,以改善和简化突破性出血或择期大手术的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Emicizumab is a bispecific, chimeric, humanized immunoglobulin G (IgG)4 that mimics the procoagulant activity of factor (F) VIII (FVIII). Its long half-life and subcutaneous route of administration have been life-changing in treating patients with hemophilia A (HA) with or without FVIII inhibitors. However, emicizumab only partially mimics FVIII activity; it prevents but does not treat acute bleeds. Emergency management is particularly complicated in patients with FVIII inhibitors receiving emicizumab prophylaxis in whom exogenous FVIII is inefficient. We have shown recently that Imlifidase (IdeS), a bacterial IgG-degrading enzyme, efficiently eliminates human anti-FVIII IgG in a mouse model of severe HA with inhibitors and opens a therapeutic window for the administration of exogenous FVIII. OBJECTIVES: To investigate the impact of IdeS treatment in inhibitor-positive HA mice injected with emicizumab. METHODS: IdeS was injected to HA mice reconstituted with human neutralizing anti-FVIII IgG and treated with emicizumab. RESULTS: IdeS hydrolyzed emicizumab in vitro and in vivo, albeit, at slower rates than another recombinant human monoclonal IgG4. While F(ab')2 fragments were rapidly cleared from the circulation, thus leading to a rapid loss of emicizumab procoagulant activity, low amounts of single-cleaved intermediate IgG persisted for several days. Moreover, the IdeS-mediated elimination of the neutralizing anti-FVIII IgG and restoration of the hemostatic efficacy of exogenous FVIII were not impaired by the presence of emicizumab and polyclonal human IgG in inhibitor-positive HA mice. CONCLUSION: Our results suggest that IdeS could be administered to inhibitor-positive patients with HA receiving emicizumab prophylaxis to improve and ease the management of breakthrough bleeds or programmed major surgeries.
引用
- Bou-Jaoudeh M, Mimoun A, Delignat S, et al. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab. J Thromb Haemost. 2023. PMID: 37473843. doi:10.1016/j.jtha.2023.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。